Results 221 to 230 of about 45,092,884 (254)

A Multicenter, Mixed Methods Study of United States Heart Teams and Health Policy: The EVOLVE Study Design and Protocol. [PDF]

J Soc Cardiovasc Angiogr Interv
Coylewright M, Kolte D, Kruse G, Suri RM, Elmariah S, Strong SR, Perpetua EM.   +6 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Seasonality of anti-Leishmania infantum titers in dogs: a crucial factor for designing effective clinical trials

Frontiers in Veterinary Science
Maria Alfonsa Cavalera, Oana Gusatoaia, Andrea Zatelli   +2 more
doaj   +1 more source

PCORnet®: An Infrastructure Supporting Innovation in Clinical Study Design. [PDF]

Med Care
Hernandez AF, Shenkman E, McTigue K, Kepler L, Cohen LW, Jolles MP, Rothman RL, Block JP, Carton TW, Tobin J, Priest EL, Evans C, Heintzman J, Williams DA.   +13 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Study Design of the Global Prospective Hemolytic Disease of the Fetus and Newborn Registry (GERANIUM). [PDF]

Am J Perinatol
Tjoa ML, Orillion A, Mankoski R, Imran N, Mao C, Krumme A, Van Hoorde S, Linares-Rivas Rico B, Komatsu Y.   +8 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Efficacy and safety of minocycline in the treatment of intracerebral haemorrhage: study design and protocol for a multicentre, randomised, open-label, blinded endpoint clinical trial. [PDF]

Eur Stroke J
Qu Y, Guo ZN, Qi S, Abuduxukuer R, Zhang P, Li H, Lv XN, Xu ZX, Yang Y, ENHANCE Protocol Steering Group.   +9 more
europepmc   +1 more source

The Danish National Survey of Diet and Physical Activity (DANSDA) 2021-2024: Study Design and Participants Characteristics. [PDF]

Nutrients
Christensen C, Biltoft-Jensen AP, Matthiessen J, Henriksen K, Sørensen MR, Christensen T, Trolle E, Fagt S.   +7 more
europepmc   +1 more source

Proposed study design for estimating COVID-19 vaccine effectiveness in post-pandemic Taiwan. [PDF]

J Chin Med Assoc
Chen LS, Lee CY, Kuo HW, Liu YL, Chuang JH.   +4 more
europepmc   +1 more source